Cargando…

Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation

Case of a patient with acute myeloid leukemia (AML) positive for mutations in both genes NPM1 and FLT3-ITD who underwent two allogeneic haematopoietic stem cell transplants (HSCT); the second allograft one was followed by extramedullary relapse (granulocytic sarcoma of right breast), with blast cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Iannotta, R., Celentano, M., Marotta, S., Pedata, C.M., Riccardi, C., Migliaccio, I., Viola, A., Muggianu, S.M., Falco, C., Bovenzi, D, Ferrara, F., Picardi, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358450/
https://www.ncbi.nlm.nih.gov/pubmed/35958243
http://dx.doi.org/10.1016/j.lrr.2022.100340
_version_ 1784763933744168960
author Iannotta, R.
Celentano, M.
Marotta, S.
Pedata, C.M.
Riccardi, C.
Migliaccio, I.
Viola, A.
Muggianu, S.M.
Falco, C.
Bovenzi, D
Ferrara, F.
Picardi, A.
author_facet Iannotta, R.
Celentano, M.
Marotta, S.
Pedata, C.M.
Riccardi, C.
Migliaccio, I.
Viola, A.
Muggianu, S.M.
Falco, C.
Bovenzi, D
Ferrara, F.
Picardi, A.
author_sort Iannotta, R.
collection PubMed
description Case of a patient with acute myeloid leukemia (AML) positive for mutations in both genes NPM1 and FLT3-ITD who underwent two allogeneic haematopoietic stem cell transplants (HSCT); the second allograft one was followed by extramedullary relapse (granulocytic sarcoma of right breast), with blast cells positive for FLT3-ITDmutation.  Treatment with Gilteritinib, a second generation selective oral type I FLT3 inhibitor, was started after the second HSCT with complete regression of breast granulocytic sarcoma in absence of hematological and extra hematologic toxicity. We conclude that Gilteritinib can represent an effective therapy for extra hematologic relapse, with acceptable toxicity and outpatient management.
format Online
Article
Text
id pubmed-9358450
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-93584502022-08-10 Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation Iannotta, R. Celentano, M. Marotta, S. Pedata, C.M. Riccardi, C. Migliaccio, I. Viola, A. Muggianu, S.M. Falco, C. Bovenzi, D Ferrara, F. Picardi, A. Leuk Res Rep Article Case of a patient with acute myeloid leukemia (AML) positive for mutations in both genes NPM1 and FLT3-ITD who underwent two allogeneic haematopoietic stem cell transplants (HSCT); the second allograft one was followed by extramedullary relapse (granulocytic sarcoma of right breast), with blast cells positive for FLT3-ITDmutation.  Treatment with Gilteritinib, a second generation selective oral type I FLT3 inhibitor, was started after the second HSCT with complete regression of breast granulocytic sarcoma in absence of hematological and extra hematologic toxicity. We conclude that Gilteritinib can represent an effective therapy for extra hematologic relapse, with acceptable toxicity and outpatient management. Elsevier 2022-07-27 /pmc/articles/PMC9358450/ /pubmed/35958243 http://dx.doi.org/10.1016/j.lrr.2022.100340 Text en © 2022 The Authors. Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Iannotta, R.
Celentano, M.
Marotta, S.
Pedata, C.M.
Riccardi, C.
Migliaccio, I.
Viola, A.
Muggianu, S.M.
Falco, C.
Bovenzi, D
Ferrara, F.
Picardi, A.
Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation
title Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation
title_full Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation
title_fullStr Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation
title_full_unstemmed Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation
title_short Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation
title_sort gilteritinib as treatment for extra-medullary relapse of flt3-itd acute myeloid leukemia flt3-itd, after allogeneic haematopoietic stem cell transplantation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358450/
https://www.ncbi.nlm.nih.gov/pubmed/35958243
http://dx.doi.org/10.1016/j.lrr.2022.100340
work_keys_str_mv AT iannottar gilteritinibastreatmentforextramedullaryrelapseofflt3itdacutemyeloidleukemiaflt3itdafterallogeneichaematopoieticstemcelltransplantation
AT celentanom gilteritinibastreatmentforextramedullaryrelapseofflt3itdacutemyeloidleukemiaflt3itdafterallogeneichaematopoieticstemcelltransplantation
AT marottas gilteritinibastreatmentforextramedullaryrelapseofflt3itdacutemyeloidleukemiaflt3itdafterallogeneichaematopoieticstemcelltransplantation
AT pedatacm gilteritinibastreatmentforextramedullaryrelapseofflt3itdacutemyeloidleukemiaflt3itdafterallogeneichaematopoieticstemcelltransplantation
AT riccardic gilteritinibastreatmentforextramedullaryrelapseofflt3itdacutemyeloidleukemiaflt3itdafterallogeneichaematopoieticstemcelltransplantation
AT migliaccioi gilteritinibastreatmentforextramedullaryrelapseofflt3itdacutemyeloidleukemiaflt3itdafterallogeneichaematopoieticstemcelltransplantation
AT violaa gilteritinibastreatmentforextramedullaryrelapseofflt3itdacutemyeloidleukemiaflt3itdafterallogeneichaematopoieticstemcelltransplantation
AT muggianusm gilteritinibastreatmentforextramedullaryrelapseofflt3itdacutemyeloidleukemiaflt3itdafterallogeneichaematopoieticstemcelltransplantation
AT falcoc gilteritinibastreatmentforextramedullaryrelapseofflt3itdacutemyeloidleukemiaflt3itdafterallogeneichaematopoieticstemcelltransplantation
AT bovenzid gilteritinibastreatmentforextramedullaryrelapseofflt3itdacutemyeloidleukemiaflt3itdafterallogeneichaematopoieticstemcelltransplantation
AT ferraraf gilteritinibastreatmentforextramedullaryrelapseofflt3itdacutemyeloidleukemiaflt3itdafterallogeneichaematopoieticstemcelltransplantation
AT picardia gilteritinibastreatmentforextramedullaryrelapseofflt3itdacutemyeloidleukemiaflt3itdafterallogeneichaematopoieticstemcelltransplantation